Get the Stockscreener App
15.61
1.14%
-0.18
After Hours:
15.60
-0.010
-0.06%
Moonlake Immunotherapeutics stock is traded at $15.61, with a volume of 1.01M.
It is down -1.14% in the last 24 hours and down -13.71% over the past month.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
See More
Previous Close:
$15.79
Open:
$15.82
24h Volume:
1.01M
Relative Volume:
0.46
Market Cap:
$1.11B
Revenue:
-
Net Income/Loss:
$-145.21M
P/E Ratio:
-6.787
EPS:
-2.3
Net Cash Flow:
$-140.12M
1W Performance:
+5.69%
1M Performance:
-13.71%
6M Performance:
-71.54%
1Y Performance:
-64.74%
1-Day Range:
$15.27
$15.82
1-Week Range:
$14.82
$16.15
52-Week Range:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Name
Moonlake Immunotherapeutics
Sector
Industry
Phone
41 41 510 8022
Address
DORFSTRASSE 29, ZUG
Compare MLTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
15.61 | 1.12B | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-15-26 | Downgrade | Goldman | Neutral → Sell |
| Jan-09-26 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-02-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-01-25 | Downgrade | Goldman | Buy → Neutral |
| Sep-30-25 | Downgrade | Citigroup | Buy → Neutral |
| Sep-30-25 | Downgrade | Wolfe Research | Outperform → Underperform |
| Sep-29-25 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-29-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-29-25 | Downgrade | Stifel | Buy → Hold |
| Jul-28-25 | Initiated | Rothschild & Co Redburn | Neutral |
| May-19-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-17-25 | Upgrade | Goldman | Neutral → Buy |
| Nov-05-24 | Resumed | Wedbush | Outperform |
| Aug-26-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Nov-02-23 | Initiated | Stifel | Buy |
| Sep-14-23 | Downgrade | Bryan Garnier | Buy → Neutral |
| Aug-31-23 | Initiated | Needham | Buy |
| Jun-15-23 | Initiated | Barclays | Equal Weight |
| May-01-23 | Initiated | Guggenheim | Buy |
| Mar-22-23 | Initiated | Wedbush | Outperform |
| Mar-09-23 | Initiated | BTIG Research | Buy |
| Feb-14-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-02-23 | Initiated | Bryan Garnier | Buy |
| Nov-11-22 | Initiated | Jefferies | Buy |
| Aug-25-22 | Initiated | SVB Leerink | Outperform |
| Jul-21-22 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Initiated | Cowen | Outperform |
View All
Moonlake Immunotherapeutics Stock (MLTX) Latest News
MoonLake Immunotherapeutics (NASDAQ:MLTX) Institutional Owners May Be Pleased With Recent Gains After 64% Loss Over the Past Year - 富途牛牛
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Recent Share Price Volatility - simplywall.st
BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
BTIG Maintains Buy on MLTX (MoonLake Immunotherapeutics) Feb 2026 - Meyka
BTIG Reiterates Buy Rating for MoonLake (MLTX) with $24 Price Ta - GuruFocus
BTIG Research Reiterates "Buy" Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
BTIG reiterates Buy rating on Moonlake Immunotherapeutics stock ahead of data - Investing.com India
MoonLake Immunotherapeutics: Fast-Track Sonelokimab and Multi-Indication Late-Stage Catalysts Underpin Buy Rating and $32 Target - TipRanks
MoonLake Immunotherapeutics (MLTX) Is Down 7.5% After FDA Fast Track Nod For Sonelokimab In PPP – Has The Bull Case Changed? - simplywall.st
MoonLake Finds Its Footing as FDA Wins Reset the Risk-Reward Profile - Investing.com
Two publications and an FDA fast track designation for Swiss biotechs - Startupticker.ch
(MLTX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
MoonLake Immunotherapeutics (MLTX) Stock Analysis: Assessing Growth Potential with an 18% Upside - DirectorsTalk Interviews
A Look At MoonLake Immunotherapeutics (MLTX) Valuation After Mixed Analyst Calls And FDA Fast Track Decision - simplywall.st
BioTech Breakout: MoonLake Up 30% On FDA Wins - Finviz
MoonLake Immunotherapeutics' (MLTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Buy rating on Moonlake stock with $32 target - Investing.com Nigeria
MoonLake Immunotherapeutics (NASDAQ:MLTX) Sees Large Growth in Short Interest - MarketBeat
Goldman Sachs Notes VELA-2 Failure, Calls MoonLake Immunotherapeutics (MLTX) a High-Risk Play - Finviz
MoonLake stock surges after FDA grants Fast Track designation for PPP treatment - Investing.com Nigeria
MoonLake Says FDA Grants its Sonelokimab Fast Track Designation for Palmoplantar Pustulosis Treatment - marketscreener.com
MoonLake announces FDA granted Fast Track designation for sonelokimab - TipRanks
MoonLake Immunotherapeutics Receives FDA Fast Track Designation for Sonelokimab in Treating Moderate-to-Severe Palmoplantar Pustulosis - Quiver Quantitative
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day - The Manila Times
FDA Fast Tracks MoonLake drug for severe palmoplantar pustulosis - Stock Titan
Aug Fed Impact: What is the cash position of MoonLake Immunotherapeutics2025 Historical Comparison & Fast Entry High Yield Tips - baoquankhu1.vn
Weekly Earnings: What are the risks of holding Tesla IncQuarterly Trade Report & Short-Term High Return Strategies - baoquankhu1.vn
Aug Opening: What is the Moat Score of MoonLake ImmunotherapeuticsJuly 2025 News Drivers & Growth Focused Entry Point Reports - baoquankhu1.vn
Portfolio Update: Does MoonLake Immunotherapeutics have declining or rising EPSBreakout Watch & Weekly High Return Forecasts - baoquankhu1.vn
How MoonLake Immunotherapeutics stock performs in weak economyWeekly Gains Report & Short-Term Trading Opportunity Alerts - mfd.ru
Can MoonLake Immunotherapeutics keep up with sector leadersMarket Activity Recap & AI Based Buy/Sell Signal Reports - mfd.ru
Biotech investor Cormorant secures $150M for another SPAC deal - BioPharma Dive
(MLTX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Risk Analysis: What is the implied volatility of JWEL2025 Bull vs Bear & High Yield Stock Recommendations - baoquankhu1.vn
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 4.6%Here's What Happened - MarketBeat
Zacks Research Downgrades MoonLake Immunotherapeutics (NASDAQ:MLTX) to Strong Sell - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
MLTX Stock Erases Most Of 2025 Loses As Wall Street, Retail Bets On FDA Feedback For Sonelokimab - MSN
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $33 - 富途牛牛
MoonLake Immunotherapeutics (MLTX) Stock Analysis: Exploring a Biotech Innovator’s Growth Potential with an 11% Upside - DirectorsTalk Interviews
MoonLake shares surge after FDA outlines approval route for HS therapy - MSN
Forecast Cut: Can TRINI deliver alphaRate Cut & Risk Managed Investment Entry Signals - baoquankhu1.vn
MoonLake Immunotherapeutics (MLTX) Is Down 7.4% After FDA Clears HS BLA Path Using Existing Trials - simplywall.st
MoonLake Immunotherapeutics (MLTX) Valuation After FDA BLA Green Light And Split Analyst Reactions - simplywall.st
Moonlake surges as no additional studies are required for lead drug - MSN
Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky Before December 15, 2025 to Join Class Action - TMX Newsfile
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap DownHere's Why - MarketBeat
Goldman Sachs downgrades Moonlake Immunotherapeutics stock to Sell on HS approval concerns By Investing.com - Investing.com South Africa
MoonLake downgraded to Sell at Goldman Sachs (MLTX:NASDAQ) - Seeking Alpha
Goldman Sachs Downgrades MoonLake Immunotherapeutics(MLTX.US) to Sell Rating, Raises Target Price to $10 - 富途资讯
Goldman Sachs Downgrades MLTX, Raises Price Target to $10.00 | M - GuruFocus
Moonlake Immunotherapeutics Stock (MLTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):